Gsk (GLAXF) Accounts Payables (2009 - 2026)

Gsk's Accounts Payables history runs 18 years deep, the most recent figure standing at -$19.3 billion for Q1 2026.

• In Q1 2026, Accounts Payables fell 1.29% year-over-year to -$19.3 billion; the TTM figure through Mar 2026 stood at -$19.3 billion (down 1.29% YoY), while the FY2025 annual figure was -$20.3 billion, down 203.46% from the prior year.
• Accounts Payables was -$19.3 billion for Q1 2026 at Gsk, up from -$20.5 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $19.7 billion in Q4 2024 to a low of -$21.2 billion in Q3 2025.
• Historically, Accounts Payables has averaged -$11.4 billion across 5 years, with a median of -$18.6 billion in 2022.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 79.07% in 2022, then slumped 311.35% in 2023.
• A 5-year view of Accounts Payables shows it stood at $19.1 billion in 2022, then rose by 3.09% to $19.7 billion in 2023, then climbed by 0.09% to $19.7 billion in 2024, then plunged by 203.95% to -$20.5 billion in 2025, then advanced by 5.54% to -$19.3 billion in 2026.
• The last three Accounts Payables figures came in at -$19.3 billion (Q1 2026), -$20.5 billion (Q4 2025), and -$21.2 billion (Q3 2025), per Business Quant data.